Research and Markets (http://www.researchandmarkets.com/research/051a60/india_pharmaceutic) has announced the addition of the "India Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
The India Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on the India's pharmaceuticals and healthcare industry.
In the Q409 update of BMI's India Pharmaceuticals & Healthcare report, we have introduced our 10-year Drug Expenditure Forecast Model. The country's US$14.23bn pharmaceutical market is forecast to reach a value of US$44.99bn by 2018, representing a compound annual growth rate (CAGR) of 12.20%. The main drivers of growth are a booming economy, increasing access to medicines, more investment in healthcare infrastructure and a greater incidence of chronic diseases.
India's intellectual property (IP) regime is far below international standards; however, there are signs that this situation is changing. In August 2009, health activists and some generic drug companies severely criticised the Indian Commerce Ministry's decision to accept the Mashelkar committee's recommendations to grant patents to new drugs. The adoption of the recommendations indicates that new patents will be allowed on incremental innovation under Section 3(d) of the Indian Patent Act, in the event that the candidate drug offers enhanced therapeutic efficacy. Patent experts supported the decision as it is in line with international norms.